Shares of Corcept Therapeutics jumped more than 32% to a nearly two-month high after the U.S. health regulator approved its lead drug for an aggressive form of ovarian cancer that is no longer responsive to standard treatment. The approval is a transformative commercial milestone for the company and drove a material intraday share price move, signaling strong investor appetite.
Shares of Corcept Therapeutics jumped more than 32% to a nearly two-month high after the U.S. health regulator approved its lead drug for an aggressive form of ovarian cancer that is no longer responsive to standard treatment. The approval is a transformative commercial milestone for the company and drove a material intraday share price move, signaling strong investor appetite.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
extremely positive
Sentiment Score
0.90
Ticker Sentiment
